[{"id":"3fa01a58-7978-4f92-b72c-b0834cad99cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05685004","created_at":"2023-01-13T14:59:18.839Z","updated_at":"2024-07-02T16:35:06.778Z","phase":"Phase 2/3","brief_title":"Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)","source_id_and_acronym":"NCT05685004","lead_sponsor":"TVAX Biomedical","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • TVI-Brain-1"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 09/15/2023","start_date":" 09/15/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-30"},{"id":"214190d1-a059-4c23-b4d3-23fda520905e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01081223","created_at":"2021-01-18T04:15:50.013Z","updated_at":"2024-07-02T16:35:46.685Z","phase":"Phase 1/2","brief_title":"Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma","source_id_and_acronym":"NCT01081223","lead_sponsor":"TVAX Biomedical","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TVI-Brain-1"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2023-06-01"}]